% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lorio:861467,
      author       = {Lorio, Sara and Sambataro, Fabio and Bertolino, Alessandro
                      and Draganski, Bogdan and Dukart, Jürgen},
      title        = {{T}he {C}ombination of {DAT}-{SPECT}, {S}tructural and
                      {D}iffusion {MRI} {P}redicts {C}linical {P}rogression in
                      {P}arkinson’s {D}isease},
      journal      = {Frontiers in aging neuroscience},
      volume       = {11},
      issn         = {1663-4365},
      address      = {Lausanne},
      publisher    = {Frontiers Research Foundation},
      reportid     = {FZJ-2019-01932},
      pages        = {57},
      year         = {2019},
      note         = {FUNDINGData used in the preparation of this article were
                      obtainedfrom the PPMI database (www.ppmi-info.org/data). For
                      up-to-date information on the study, visit
                      www.ppmi-info.org.PPMI – a public-private partnership –
                      is funded by theMichael J. Fox Foundation for Parkinson’s
                      Research andfunding partners, including Abbvie, Avid
                      Radiopharmaceuticals,Biogen Idec, Briston-Myers Squibb,
                      Covance, GE Healthcare,Genentech, GlaxoSmithKline, Lilly,
                      Lundbeck, Merck, MesoScale Discovery, Pfizer, Piramal,
                      Roche, and UCB. SL wassupported by the National Institute
                      for Health ResearchBiomedical Research Centre at Great
                      Ormond Street Hospitalfor Children NHS Foundation Trust, The
                      Henry Smith Charity,and Action Medical Research (GN2214). BD
                      was supportedby the Swiss National Science Foundation
                      (project grant $no.32003B_159780$ and SPUM
                      $33CM30_140332/1),$ FoundationParkinson Switzerland,
                      Foundation Synapsis. LREN is gratefulto the Roger de
                      Spoelberch and the Partridge Foundations fortheir generous
                      support},
      abstract     = {There is an increasing interest in identifying non-invasive
                      biomarkers of disease severityand prognosis in idiopathic
                      Parkinson’s disease (PD). Dopamine-transporter
                      SPECT(DAT-SPECT), diffusion tensor imaging (DTI), and
                      structural magnetic resonance imaging(sMRI) provide unique
                      information about the brain’s neurotransmitter and
                      microstructuralproperties. In this study, we evaluate the
                      relative and combined capability of theseimaging modalities
                      to predict symptom severity and clinical progression inde
                      novoPDpatients. To this end, we used MRI, SPECT, and
                      clinical data ofde novodrug-naïvePD patients (n= 205, mean
                      age 61±10) and age-, sex-matched healthy controls(n= 105,
                      mean age 58±12) acquired at baseline. Moreover, we employed
                      clinical dataacquired at 1 year follow-up for PD patients
                      with or withoutL-Dopa treatment in orderto predict the
                      progression symptoms severity. Voxel-based group comparisons
                      andcovariance analyses were applied to characterize baseline
                      disease-related alterations forDAT-SPECT, DTI, and sMRI.
                      Cortical and subcortical alterations inde novoPD
                      patientswere found in all evaluated imaging modalities, in
                      line with previously reported midbrain-striato-cortical
                      network alterations. The combination of these imaging
                      alterations wasreliably linked to clinical severity and
                      disease progression at 1 year follow-up in thispatient
                      population, providing evidence for the potential use of
                      these modalities asimaging biomarkers for disease severity
                      and prognosis that can be integrated intoclinical trials.},
      cin          = {INM-7},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-7-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30930768},
      UT           = {WOS:000461685400001},
      doi          = {10.3389/fnagi.2019.00057},
      url          = {https://juser.fz-juelich.de/record/861467},
}